Top

The Journal of Prevention of Alzheimer's Disease

Published in:

01-04-2023 | Alzheimer's Disease | Original Research

Forecasting the Prevalence of Alzheimer’s Disease at Mild Cognitive Impairment and Mild Dementia Stages in France in 2022

Authors: Audrey Gabelle, M. Guéry, A. Doutriaux, K. Bettayeb

Published in: The Journal of Prevention of Alzheimer's Disease | Issue 2/2023

Abstract

Background

Given the evolution of early diagnosis guidelines and future disease-modifying therapies, estimating the prevalence of Alzheimer’s disease (AD) at early stages is key.

Objective

To estimate the number of people living with mild cognitive impairment (MCI) due to AD and mild AD dementia in France in 2022 that could be eligible to future AD therapies.

Methods

A step-by-step approach was defined based on disease stages definition and clinical practice. In line with AD guidelines, amyloid-positive profile is considered in our estimates to enhance the diagnosis accuracy of early stages of AD. Age-stratified prevalence from French cohort and international pooled analyses were identified to feed the different steps. To consider uncertainty around mean prevalence values, low and high scenarii based on the lower and upper bounds of the 95% confidence interval were conducted.

Results

We estimated that 2.5 (low scenario: 1.7–high scenario: 3.6) million people suffer from mild cognitive impairment in France in 2022 among whom 1.65 (low: 1.5–high: 1.8) million people meet the criteria for mild cognitive impairment due to AD i.e., with amyloid positive profile. The expected number of clinical AD dementia is estimated at 925,886 people. Among those, 379,278 people suffer from mild AD dementia based on clinical diagnosis, including 311,043 (low: 289,174–high: 328,332) cases with amyloid positive profile.

Conclusion

MCI due to AD, and mild dementia stages are potentially of high prevalence. Population-based studies are needed to confirm those estimates.

Wolters FJ, Chibnik LB, Waziry R, et al. Twenty-seven-year time trends in dementia incidence in Europe and the United States: The Alzheimer Cohorts Consortium. Neurology. 2020;95(5):e519–e531. doi:https://doi.org/10.1212/WNL.0000000000010022CrossRefPubMedPubMedCentral

Matthews FE, Stephan BCM, Robinson L, et al. A two decade dementia incidence comparison from the Cognitive Function and Ageing Studies I and II. Nat Commun. 2016;7(1):11398. doi:https://doi.org/10.1038/ncomms11398CrossRefPubMedPubMedCentral

Satizabal CL, Beiser AS, Chouraki V, Chêne G, Dufouil C, Seshadri S. Incidence of Dementia over Three Decades in the Framingham Heart Study. N Engl J Med. 2016;374(6):523–532. doi:https://doi.org/10.1056/NEJMoa1504327CrossRefPubMedPubMedCentral

GBD 2019 Dementia Forecasting Collaborators. Estimation of the global prevalence of dementia in 2019 and forecasted prevalence in 2050: an analysis for the Global Burden of Disease Study 2019. Lancet Public Health. 2022;7(2):e105–e125. doi:https://doi.org/10.1016/S2468-2667(21)00249-8CrossRef

Jacqmin-Gadda H, Alperovitch A, Montlahuc C, et al. 20-Year prevalence projections for dementia and impact of preventive policy about risk factors. Eur J Epidemiol. 2013;28(6):493–502. doi:https://doi.org/10.1007/s10654-013-9818-7CrossRefPubMed

The Economist Intelligence Unit. Assessing the socioeconomic impact of Alzheimer’s disease in Western Europe and Canada. The Economist. 2017. https://www.ceafa.es/files/2017/05/Evaluaci%C3%B3n%20del%20impacto%20socioecon%C3%B3mico%20de%20la%20enfermedad%20de%20Alzheimer%20en%20Europa%20Occidental%20y%20Canad%C3%A1-1.pdf

Zissimopoulos J, Crimmins E, St Clair P. The Value of Delaying Alzheimer’s Disease Onset. Forum Health Econ Policy. 2014;18(1):25–39. doi:https://doi.org/10.1515/fhep-2014-0013CrossRefPubMedPubMedCentral

Jack CR, Bennett DA, Blennow K, et al. NIA-AA Research Framework: Toward a biological definition of Alzheimer’s disease. Alzheimers Dement. 2018;14(4):535–562. doi:https://doi.org/10.1016/j.jalz.2018.02.018CrossRefPubMedPubMedCentral

Albert MS, DeKosky ST, Dickson D, et al. The diagnosis of mild cognitive impairment due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement. 2011;7(3):270–279. doi:https://doi.org/10.1016/j.jalz.2011.03.008CrossRefPubMedPubMedCentral

10.

Orgeta V, Mukadam N, Sommerlad A, Livingston G. The Lancet Commission on Dementia Prevention, Intervention, and Care: a call for action. Ir J Psychol Med. 2019;36(2):85–88. doi:https://doi.org/10.1017/ipm.2018.4CrossRefPubMed

11.

Ankri J, Van Broeckhoven C. Evaluation Du Plan Alzheimer 2008–2012. Solidarités Santé; 2013. https://solidarites-sante.gouv.fr/IMG/pdf/Rapport-evaluation-plan-alzheimer-2012.pdf

12.

Grand A, Joanette Y. Plan Maladies Neurodégénératives 2014–2019. Solidarités Santé https://solidarites-sante.gouv.fr/IMG/pdf/pmnd-rapport-evaluation.pdf

13.

Ministère des Solidarités et de la Santé. Feuille de route Maladies neurodégénératives 2021–2022. Published 2022–2021. Accessed April 12, 2022. https://solidarites-sante.gouv.fr/soins-et-maladies/maladies/maladies-neurodegeneratives/article/feuille-de-route-maladies-neuro-degeneratives-2021-2022

14.

Carcaillon-bentata L, Elbaz A, Ha C, et al. Peut-on estimer la prévalence de la maladie d’Alzheimer et autres démences à partir des bases de données médico-administratives? Comparaison aux données de cohortes populationnelles. Bulletin épidémiologique hebdomadaire (BEH). 2016;(n° 28–29):459–467.

15.

Ramaroson H, Helmer C, Barberger-Gateau P, Letenneur L, Dartigues JF, PAQUID. [Prevalence of dementia and Alzheimer’s disease among subjects aged 75 years or over: updated results of the PAQUID cohort]. Rev Neurol (Paris). 2003;159(4):405–411.PubMed

16.

Gillis C, Maruff P, Maserejian N, et al. LP22- UPDATED U.S. PREVALENCE ESTIMATES ACCOUNTING FOR RACIAL AND ETHNIC DIVERSITY FOR TRIALS AND THERAPIES TARGETING MILD COGNITIVE IMPAIRMENT DUE TO ALZHEIMER’S DISEASE (AD) AND MILD AD DEMENTIA. J Prev Alzheimers Dis. 2021;8(Suppl 1):S73–S170. doi:https://doi.org/10.14283/jpad.2021.58

17.

Potashman M, Levitchi Benea M, Gillis C, Gianinazzi M, Ikram MA, Maserejian N. PND59 Estimating the Prevalence of Aβ-Confirmed Alzheimer’s Disease Using a Funnel-Based Approach. Value in Health. 2020;23:S633–S634. doi:https://doi.org/10.1016/j.jval.2020.08.1384CrossRef

18.

McKhann GM, Knopman DS, Chertkow H, et al. The diagnosis of dementia due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement. 2011;7(3):263–269. doi:https://doi.org/10.1016/j.jalz.2011.03.005CrossRefPubMedPubMedCentral

19.

HAS. Transparency Committee doctrine_Principles of medicinal product assessments and appraisal for reimbursement purposes. 2020:28.

20.

Projections de population 2005–2050 par sexe et âge — Projections de population 2005–2050 pour la France métropolitaine I Insee. Accessed April 12, 2022. https://www.insee.fr/fr/statistiques/2530035?sommaire=2530059

21.

Petersen RC, Lopez O, Armstrong MJ, et al. Practice guideline update summary: Mild cognitive impairment: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology. Neurology. 2018;90(3):126–135. doi:https://doi.org/10.1212/WNL.0000000000004826CrossRefPubMedPubMedCentral

22.

Jansen WJ, Janssen O, Tijms BM, et al. Prevalence Estimates of Amyloid Abnormality Across the Alzheimer Disease Clinical Spectrum. JAMA Neurol. 2022;79(3):228–243. doi:https://doi.org/10.1001/jamaneurol.2021.5216CrossRefPubMed

23.

Dubois B, Feldman HH, Jacova C, et al. Advancing research diagnostic criteria for Alzheimer’s disease: the IWG-2 criteria. Lancet Neurol. 2014;13(6):614–629. doi:https://doi.org/10.1016/S1474-4422(14)70090-0CrossRefPubMed

24.

Alzheimer Europe. Estimating the Prevalence of Dementia in Europe. Dementia in Europe Yearbook. 2019.; 2019. https://www.alzheimer-europe.org/sites/default/files/alzheimer_europe_dementia_in_europe_yearbook_2019.pdf

25.

Mouton-Liger F, Wallon D, Troussière AC, et al. Impact of cerebro-spinal fluid biomarkers of Alzheimer’s disease in clinical practice: a multicentric study. J Neurol. 2014;261(1):144–151. doi:https://doi.org/10.1007/s00415-013-7160-3CrossRefPubMed

26.

Rabinovici GD, Gatsonis C, Apgar C, et al. Association of Amyloid Positron Emission Tomography With Subsequent Change in Clinical Management Among Medicare Beneficiaries With Mild Cognitive Impairment or Dementia. JAMA. 2019;321(13):1286–1294. doi:https://doi.org/10.1001/jama.2019.2000CrossRefPubMedPubMedCentral

27.

Robinson RL, Rentz DM, Bruemmer V, et al. Observation of Patient and Caregiver Burden Associated with Early Alzheimer’s Disease in the United States: Design and Baseline Findings of the GERAS-US Cohort Study1. J Alzheimers Dis. 2019;72(1):279–292. doi:https://doi.org/10.3233/JAD-190430CrossRefPubMedPubMedCentral

28.

Helmer C, Pasquier F, Dartigues JF. Épidémiologie de la maladie d’Alzheimer et des syndromes apparentés. Med Sci (Paris). 2006;22(3):288–296. doi:https://doi.org/10.1051/medsci/2006223288CrossRefPubMed

29.

Epelbaum S, Paquet C, Hugon J, et al. How many patients are eligible for disease-modifying treatment in Alzheimer’s disease? A French national observational study over 5 years. BMJ Open. 2019;9(6):e029663. doi:https://doi.org/10.1136/bmjopen-2019-029663CrossRefPubMedPubMedCentral

30.

Hanon O, Vidal JS, Lehmann S, et al. Plasma amyloid beta predicts conversion to dementia in subjects with mild cognitive impairment: The BALTAZAR study. Alzheimers Dement. February 20, 2022. doi:https://doi.org/10.1002/alz.12613

31.

Hanon O, Vidal JS, Lehmann S, et al. Plasma amyloid levels within the Alzheimer’s process and correlations with central biomarkers. Alzheimers Dement. 2018;14(7):858–868. doi:https://doi.org/10.1016/j.jalz.2018.01.004CrossRefPubMed

32.

Dufouil C, Dubois B, Vellas B, et al. Cognitive and imaging markers in non-demented subjects attending a memory clinic: study design and baseline findings of the MEMENTO cohort. Alzheimers Res Ther. 2017;9(1):67. doi:https://doi.org/10.1186/s13195-017-0288-0CrossRefPubMedPubMedCentral

33.

Petersen RC, Roberts RO, Knopman DS, et al. Prevalence of mild cognitive impairment is higher in men. The Mayo Clinic Study of Aging. Neurology. 2010;75(10):889–897. doi:https://doi.org/10.1212/WNL.0b013e3181f11d85CrossRefPubMedPubMedCentral

34.

Ganguli M, Dodge HH, Shen C, DeKosky ST. Mild cognitive impairment, amnestic type: an epidemiologic study. Neurology. 2004;63(1):115–121. doi:https://doi.org/10.1212/01.wnl.0000132523.27540.81CrossRefPubMed

35.

Koivisto K, Reinikainen KJ, Hänninen T, et al. Prevalence of age-associated memory impairment in a randomly selected population from eastern Finland. Neurology. 1995;45(4):741–747. doi:https://doi.org/10.1212/wnl.45.4.741CrossRefPubMed

36.

Di Carlo A, Lamassa M, Baldereschi M, et al. CIND and MCI in the Italian elderly: frequency, vascular risk factors, progression to dementia. Neurology. 2007;68(22):1909–1916. doi:https://doi.org/10.1212/01.wnl.0000263132.99055.0dCrossRefPubMed

37.

Larrieu S, Letenneur L, Orgogozo JM, et al. Incidence and outcome of mild cognitive impairment in a population-based prospective cohort. Neurology. 2002;59(10):1594–1599. doi:https://doi.org/10.1212/01.wnl.0000034176.07159.f8CrossRefPubMed

38.

Kivipelto M, Helkala EL, Hänninen T, et al. Midlife vascular risk factors and late-life mild cognitive impairment: A population-based study. Neurology. 2001;56(12):1683–1689. doi:https://doi.org/10.1212/wnl.56.12.1683CrossRefPubMed

39.

Hänninen T, Hallikainen M, Tuomainen S, Vanhanen M, Soininen H. Prevalence of mild cognitive impairment: a population-based study in elderly subjects. Acta Neurol Scand. 2002;106(3):148–154. doi:https://doi.org/10.1034/j.1600-0404.2002.01225.xCrossRefPubMed

40.

Solfrizzi V, Panza F, Colacicco AM, et al. Vascular risk factors, incidence of MCI, and rates of progression to dementia. Neurology. 2004;63(10):1882–1891. doi:https://doi.org/10.1212/01.wnl.0000144281.38555.e3CrossRefPubMed

41.

Coronavirus: morts par âge en France 2022. Statista. Accessed April 12, 2022. https://fr.statista.com/statistiques/1104103/victimes-coronavirus-age-france/

42.

INSERM. Maladie d’Alzheimer: Enjeux Scientifiques, Médicaux et Sociétaux.; 2007. Accessed April 12, 2022. https://www.ipubli.inserm.fr/handle/10608/72

43.

Epelbaum S. Prévention pharmacologique du déclin cognitif et de l’autonomie:… Accessed April 12, 2022. https://www.edimark.fr/correspondances-mc-v/prevention-pharmacologique-nbsp-declin-nbsp-cognitif-autonomie-quelle-est-population-cible

Title: Forecasting the Prevalence of Alzheimer’s Disease at Mild Cognitive Impairment and Mild Dementia Stages in France in 2022
Authors: Audrey Gabelle
M. Guéry
A. Doutriaux
K. Bettayeb
Publication date: 01-04-2023
Publisher: Springer International Publishing
Keywords: Alzheimer's Disease
Alzheimer's Disease
Mild Neurocognitive Disorder
Dementia
Dementia
Published in: The Journal of Prevention of Alzheimer's Disease / Issue 2/2023
Electronic ISSN: 2426-0266
DOI: https://doi.org/10.14283/jpad.2023.22

Advances in Alzheimer's

Alzheimer's Disease
Independent Medical Education

Alzheimer's research and care is changing rapidly. Keep up with the latest developments from key international conferences, together with expert insights on how to integrate these advances into practice.

This content is intended for healthcare professionals outside of the UK.

Supported by:

Lilly

Developed by: Springer Healthcare IME

Learn more

ERS Congress 2024

Springer Medicine

Forecasting the Prevalence of Alzheimer’s Disease at Mild Cognitive Impairment and Mild Dementia Stages in France in 2022

Abstract

Background

Objective

Methods

Results

Conclusion

Advances in Alzheimer's

ERS Congress 2024

Springer Medicine

Abstract

Background

Objective

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 2/2023

Utility of Environmental Complexity as a Predictor of Alzheimer’s Disease Diagnosis: A Big-Data Machine Learning Approach

Predicting Progression from Normal to MCI and from MCI to AD Using Clinical Variables in the National Alzheimer’s Coordinating Center Uniform Data Set Version 3: Application of Machine Learning Models and a Probability Calculator

Fructose Consumption is Associated with a Higher Risk of Dementia and Alzheimer’s Disease: A Prospective Cohort Study

Predictive Utility of Plasma Amyloid and Tau for Cognitive Decline in Cognitively Normal Adults

A Large Retrospective Cohort Study on the Risk of Alzheimer’s Disease and Related Dementias in Association with Vascular Diseases and Cancer Therapy in Men with Prostate Cancer

Memory for Semantically Related Objects Differentiates Cognitively Unimpaired Autosomal Dominant Mutation Carriers from Non-Carrier Family Members

Advances in Alzheimer's